TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05836753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarecycline Tablet
Description: Each tablet contained 100 mg of Sarecycline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets of Sarecycline tablets
Description: Each tablet contained 0 mg of Sarecycline.
Study: NCT04834167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneDoc Picopulse
Description: Eligible patients will proceed to receive skin cleansing prior to OneDoc Picopulse treatment. After the cleansing, the patients will receive OneDoc Picopulse treatment for 15 mins. Patients will receive ten picopulse treatments for bi-monthly.
Study: NCT05109832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-IMP4297
Description: 14C marked IMP4297
Study: NCT06245317

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation Mode
Description: Each arm will have a different ventilation mode according to the allocation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation Mode
Description: Each arm will have a different ventilation mode according to the allocation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Ventilation Mode
Description: Each arm will have a different ventilation mode according to the allocation.
Study: NCT05977673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg IV day1
Study: NCT06104111

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 bolus at days 0, 28 and 56. Blood samples taken at days 0, 1, 28, 29, 56, 57 ad 84
Study: NCT06210100

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active iTBS
Description: Mag-TD stimulator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: Mag-TD stimulator
Study: NCT04803227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emricasan
Description: Emricasan 25 mg BID (days 1-14). Oral (capsule) administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID \*days 1-14). Oral (capsule) administration.
Study: NCT06237400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG19018
Description: ZG19018 Given by PO (mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG19018
Description: ZG19018 Given by PO (mouth)
Study: NCT05285540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-216
Description: DT-216 will be administered by intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-216 matching Placebo
Description: Placebo will be administered by intravenous (IV) injection
Study: NCT05044858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Midpoint transverse process block group
Description: After marking the level of the incision by surgeon (commonly T5- T6) The patient will be situated in the lateral position, the block area will be sterilized with povidine-iodine, and high -frequency linear ultrasound probe will be placed oblique parasagittally 3 cm lateral to the spinous process at the level of skin incision. 100-mm short bevel echogenic needle (Contiplex, B.Braun, Germany) will be inserted in plane from cranial to caudal direction. The desired end point of the needle tip will be the midpoint of the line between the posterior border of transverse process and the pleura titrated bolus of 20 ml of 0.25% bupivacaine and dexamethazone 8 mg will be injected at the target site. At end of the surgery general anaesthesia will be stopped with reversal of muscle relaxation and awakening of patient

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: General anesthesia will be induced with the same protocol and MTP block will be done but with injection of placebo (2 ml normal saline) instead of local anesthetic .~On arrival to the PACU postoperative Numerical Rating scale at rest and coughing will be recorded, analgesia will be maintained with intravenous paracetamol 1 g every 8 h and required additional rescue analgesia (morphine) at any time will be calculated.
Study: NCT04656132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity assessment, promotion and monitoring in a preventive cardiology clinic
Description: physical activity assessment promotion and remote home step-count monitoring in a clinical cardiology center
Study: NCT05448794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection
Description: ultrasound-guided hydrodilatation with hypertonic Dextrose
Study: NCT06085859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Routine nasal catheter group
Description: The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter as described in the guide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask group
Description: The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
Study: NCT05910359

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: transabdominal and transperineal ultrasound by expert sonographers

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: transabdominal and transperineal ultrasound by expert sonographers
Study: NCT05507372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide 1 MG
Description: Dopamine Receptor Antagonist - Oral Pimozide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimozide 1 MG
Description: Dopamine Receptor Antagonist - Oral Pimozide
Study: NCT04780685

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: hMSC
Description: IV administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hMSC
Description: IV administration
Study: NCT05563987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-DE
Description: The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DE
Description: DE
Study: NCT06470945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glass ceramic sectional veneer
Description: partial laminate veneer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glass ceramic laminate veneer
Description: Glass ceramic laminate veneer
Study: NCT04932083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added.
Study: NCT06267859

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The use of a combination of microelements and vitamins against the background of physiotherapy
Description: If necessary, necessary microelements and vitamins will be added to the treatment process. At the same time, physiotherapeutic procedures will be added at the rehabilitation stage.
Study: NCT05205642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)
Description: Cardiopulmonary exercise testing (CPET) using a Quark CPET metabolic cart (Rome, Italy) according to American Thoracic Society (ATS) guidelines. A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute) adapted to the patient's functional capacities according to the examiner's free judgment, up to exhaustion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Arterial Tonography (PAT) using the EndoPAT™ device
Description: A volume sensor measuring reactive hyperemia is placed on the second fingertip of both hands. First the device evaluates the baseline volume of the pulse. Then, we will apply pressure that is 50 mmHg higher than the baseline systolic pressure of the examinee on the evaluated hand for five minutes, using a sphygmomanometer cuff. After the pressure is released on the evaluated hand, the new pulse volume is tested. To neutralize the effects of the autonomous systemic response, the program divides the difference of the pulse volume in the examined hand by the difference in the untested hand and we get the Reactive Hyperemic Index (RHI) which represents the endothelial function in the tested hand. During the examination, the calculated arterial tonometry graph is generated, and out of it the RHI will be automatically calculated, using the EndoPAT2000™ program.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endothelin
Description: For Endothelin levels we will use the Endothelin ELISA kit from R\&D company, and for measurement 1 cc of serum will be needed.
Study: NCT06374511

Intervention type: DIAGNOSTIC_TEST
Intervention: Test for CMV reactivation
Description: All enrolled patients are monitored for CMV reactivation and hepatic encephalopathy using regular clinical tests or library test
Study: NCT05274269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to ELX/TEZ/IVA)
Description: Placebo matched to ELX/TEZ/IVA for oral administration.
Study: NCT06453473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TSBR
Description: The intervention consists of 20 training sessions on the PerStBiRo system (\~ twice a week within 3 months period). Each session lasts for 20 minutes and includes three parts: stage 1) warm up, stage 2) main exercise and stage 3) cool down.~Stage 1 contains 3 minutes of self-paced pedalling with the same bicycle resistance. At Stage 2, the main exercise, all participants will perform a 15-minute hands-free cycling training on the PerStBiRo system with a pulse watch to reach a training at 60%-80% of maximal pulse, including cognitive tasks projected at a screen in front of the participant. Stage 3 includes the cool down with 2 minutes of self-paced pedalling without bicycle resistance and cognitive tasks. During the training sessions, all participants will wear a loose safety harness that can arrest falling using the PerStBiRo system, but still allow comfortable pedalling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TSBR
Description: The intervention consists of 20 training sessions on the PerStBiRo system (\~ twice a week within 3 months period). Each session lasts for 20 minutes and includes three parts: stage 1) warm up, stage 2) main exercise and stage 3) cool down.~Stage 1 contains 3 minutes of self-paced pedalling with the same bicycle resistance. At Stage 2, the main exercise, all participants will perform a 15-minute hands-free cycling training on the PerStBiRo system with a pulse watch to reach a training at 60%-80% of maximal pulse, including cognitive tasks projected at a screen in front of the participant. Stage 3 includes the cool down with 2 minutes of self-paced pedalling without bicycle resistance and cognitive tasks. During the training sessions, all participants will wear a loose safety harness that can arrest falling using the PerStBiRo system, but still allow comfortable pedalling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PerTSBR
Description: Participants of the intervention group will receive a combination of lateral and medial tilting unannounced perturbations during stage 2 of the TSBR training. This will be provided by roll and pitch angles (tilt) balance perturbations that aim to evoke trunk and arm balance recovery responses.
Study: NCT06660420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given by IV
Study: NCT06605131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+Toripalimab+CCRT
Description: 1. Induction Chemotherapy (GP Regimen combined with Toripalimab):~1. GP Regimen Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing less than 40 kg: 3 mg/kg; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP+CCRT
Description: 1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles
Study: NCT04677816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Neoadjuvant Chemotherapy (NAC)
Description: Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Neoadjuvant Chemotherapy (NAC)
Description: Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Diary
Description: Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
Study: NCT05274269

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to IVA)
Description: Placebo matched to IVA for oral administration.
Study: NCT05917418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional support
Description: nutritional support
Study: NCT06368596

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fusobacterium detection
Description: One vaginal and one cervical swab will be collected from participants (both cases and controls) before surgery.~During surgical intervention, routine biopsies of the endometriotic tissue will be done for all endometriosis types; further, small biopsies of apparently healthy endometrial tissue and of healthy peritoneum will be done, as per routine procedure.~In the control group routine biopsies needed for the specific condition and small biopsies of endometrial tissue will be carried out.~During these routine biopsies, a small additional quantity of tissue will be taken, which will be analyzed for the search for Fusobacterium.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fusobacterium detection
Description: One vaginal and one cervical swab will be collected from participants (both cases and controls) before surgery.~During surgical intervention, routine biopsies of the endometriotic tissue will be done for all endometriosis types; further, small biopsies of apparently healthy endometrial tissue and of healthy peritoneum will be done, as per routine procedure.~In the control group routine biopsies needed for the specific condition and small biopsies of endometrial tissue will be carried out.~During these routine biopsies, a small additional quantity of tissue will be taken, which will be analyzed for the search for Fusobacterium.
Study: NCT05024721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP2101
Description: Test drug
Study: NCT05321862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PentixaFor
Description: Tomography by Emission of Positons (PET) with the radiopharmaceutic \[68Ga\]Ga-PentixaFor
Study: NCT04618055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NiTiDent Tuah Porous NiTi Dental Implants
Description: A newly developed NiTiDent Tuah porous NiTi cylindrical bone level dental implant measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations produced by Nitium Technology Sdn Bhd.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Dental Implant Systems
Description: A market approved bone level dental implant systems measuring 4.5 mm in diameter and 10 mm in length and an abutment system of different heights and angulations
Study: NCT05024721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2101
Description: Reference drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2101
Description: Placebo drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2102
Description: Placebo drug
Study: NCT05159115

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-FODMAP diet
Description: 4 weeks of a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch- and Sucrose Reduced Diet (SSRD)
Description: 4 weeks of a diet low in starch and sucrose
Study: NCT06391788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracoscopic Morrow surgery
Description: minimally invasive trans-mitral Morrow septal myectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified Morrow surgery
Description: median open modified enlarged Morrow septal myectomy
Study: NCT00755066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: 200 µg intranasal, 4 weeks, od.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal spray
Study: NCT05019222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane based inhalation anesthesia
Description: Sevoflurane group will be inducted with bolus of propofol 1% and maintained with sevofulrane as inhalation and TCI Minto model of remifentanil for general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam based total intravenous anesthesia
Description: Remimazolam group will be inducted with remiamazolam at 6 mg/kg/h and maintained with remimazolam at 0.5-1.5 mg/kg/h and TCI Minto model of remifentanil for general anesthesia.
Study: NCT05558293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Full mouth or quadrant SRP

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Full mouth or quadrant SRP
Study: NCT05696886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: Group A received Pethidine alone in the period between January 2021 and December 2021